No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FULC240517P8000
- 0.65
- -0.20-23.53%
15min DelayClose May 13 15:59 ET
0.80High0.40Low
0.75Open0.85Pre Close55 Volume56 Open Interest8.00Strike Price3.43KTurnover0.00%IV0.00%PremiumMay 17, 2024Expiry Date0.65Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma11.31Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
INFN, VYGR and AMSC Are Among After Hour Movers
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Express News | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Fulcrum Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 87.5% Goldman Sachs → $15 Upgrades Neutral → Buy 03/13/2024 75% RBC Capital → $14 Initiates Cov
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Comments
$Fulcrum Therapeutics(FULC.US$ Long term looking for dollar 15 range, possible 17 price target to hit. 13.7 resistance 10.4 Fulcrum
4
$Fulcrum Therapeutics(FULC.US$ Fulcrum Therapeutics Inc: Fulcrum Will Receive an Upfront Payment of $80.0 Mln
1
4
$Fulcrum Therapeutics(FULC.US$ Reuters· 2 mins ago
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
2
$Fulcrum Therapeutics(FULC.US$
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
P...
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
P...
2
$Fulcrum Therapeutics(FULC.US$ 👀 not bad ! valid float, price retest 12.14 setting me buy alert to head target 16.50
Read more